Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DTRMWXHS-12 in CLL and B-cell Lymphomas
NCT02900716Phase 1Completed
- Sponsor
- DTRM Biopharma
- Start
- Sep 2016
- Primary completion
- Nov 2020
- Modality
- Nucleic Acid-Directed Small Molecules, Covalent Small Molecules, Multivalent & Scaffold-Based Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of DTRMWXHS-12 in chronic lymphocytic leukemia (CLL) and B cell lymphoma (3 arms), sponsored by DTRM Biopharma. Primary endpoint: Number of patients with adverse events. Started Sep 2016; status: completed.
02
Drugs
DTRMWXHS-12
03
Conditions
chronic lymphocytic leukemia (CLL)B cell lymphoma
Beyond the preview
Go deeper on NCT02900716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02900716.